Case report A female patient with ALL received a bone marrow transplant (BMT) from an unrelated donor with a one A 20-year-old woman was diagnosed in June 1993 with acute lymphocytic leukemia (ALL) which subsequently locus HLA mismatch. The donor was heterozygous at the HLA-A locus, while the patient was homozygous at relapsed in the central nervous system in August 1995. She was transplanted in second complete remission with bone this locus. The patient had cytomegalovirus (CMV) antigenemia on day 42 following an intensive preparative marrow from an unrelated 30-year-old woman. The human leukocyte antigen (HLA)-A locus of patient and donor were regimen that included anti-thymocyte globulin and BU؉CY؉TBI to prevent graft rejection. Ganciclovir (2, 24) and (2, Ϫ), respectively, so that transplantation was from heterozygote to homozygote at the HLA-A locus. The was given initially for the treatment of CMV antigenemia, although the patient soon developed severe myelopreparative regimen consisted of anti-thymocyte globulin (ATG) 2.5 mg/kg for 4 days (Pasteur-Merieux, Lyon, suppression. The patient's hematopoietic recovery was poor, and CMV and human herpesvirus-6 (HHV-6) France) followed by busulfan (BU) 4 mg/kg for 2 days, cyclophosphamide (CY) 30 mg/kg for 2 days, and total were detectable in the peripheral blood. Severe CMV retinitis was treated with foscarnet and the intraocular body irradiation (TBI) 3 Gy for 4 days. She received 1.3 ϫ 10 10 nucleated cells (2.4 ϫ 10 8 cells/kg) on 15 May injection of ganciclovir. The CMV retinitis improved and the marrow gradually recovered. CMV and HHV-1996. She was CMV seropositive, though she was negative in a CMV antigenemia assay (0/50 000 cells) that detects 6 were no longer detectable in the peripheral blood. Foscarnet and intraocular injection of ganciclovir appeared pp65-positive cells in peripheral blood leukocytes with C7 antibodies and immunoperoxidase detection. 3 Graft-versusto be an effective treatment for CMV retinitis in this myelosuppressed BMT patient.
treated with prednisolone (1-2 mg/kg) and the symptoms the CMV retinitis with concomitant recovery of the neutrophil and platelet counts. Foscarnet was discontinued on of GVHD gradually disappeared by day 120.
On day 147 the patient noted a visual disturbance of her day 272. left eye. CMV retinitis was diagnosed by funduscopic examination of both eyes and PCR detection of CMV-DNA from a vitreous sample. The PCR assay for CMV and Discussion HHV-6 in the peripheral blood was also positive. She was treated with foscarnet (36 mg/kg/day infused over 2 h) We report a rare case of a BMT patient with severe myeloand immunosuppression who suffered severe CMV retinitis because ganciclovir had previously induced myelosuppression. However, the patient suffered severe nausea and vomthat was successfully treated with continuous infusion of foscarnet and intraocular injection of ganciclovir. Concomiiting from the foscarnet. The CMV retinitis rapidly progressed to both eyes. The patient lost visual acuity of the tant recovery from the myelosuppression and CMV retinitis was probably due to the effect of foscarnet against the left eye, and the retinitis threatened the fovea in the right eye. The CMV antigen test was negative (0/50 000 CMV and HHV-6 infections. ATG was added to the preparative regimen of leukocytes) and the PCR test for CMV became negative despite deterioration of the CMV retinitis ( Figure 1 ). HHV-BUϩCYϩTBI to avoid graft failure in this case with an HLA-A locus mismatch. The use of ATG in conditioning 6 DNA was still detectable in the peripheral blood. On day 182 the foscarnet was increased to 90 mg/kg/day by conregimens has been reported to induce profound lymphopenia, and consequently the incidence of CMV infections tinuous infusion. This was associated with renal dysfunction and metabolic abnormalities, including hypocalcemia, has been elevated despite the preventive use of high-titer anti-CMV IgG and acyclovir. 5 This patient had profound hypomagnesemia and hypokalemia. The renal dysfunction, exacerbated by the nephrotoxicity of CsA, was managed lymphopenia and associated CMV and HHV-6 infections that suppressed the bone marrow. Therefore, awareness of by the continuous infusion of foscarnet with hydration. On day 190 the serum creatinine increased from 1.0 to 2.1 the increased risk of viral infections after BMT is very important when ATG is used in the preparative regimen. mg/dl (normal range: 0.5-1.2 mg/dl), but gradually decreased into the normal range with hydration. Intraocular
It is well known that CMV infections in BMT patients are associated with graft failure, delayed platelet injection of ganciclovir (0.4 mg for one eye) was started on day 195 and then performed biweekly from day 230 engraftment, leukopenia, and thrombocytopenia following engraftment. 6 The myelosuppression after BMT could with the hope of achieving a synergistic effect with the foscarnet. There was no associated myelosuppression. On result from CMV infection of stromal cells and consequent perturbation of growth factors or direct infection of hematoday 220, the CMV antigen test was negative (0/50000 leukocytes), and the PCR test for CMV and HHV-6 DNA poietic progenitors. 7,8 Several mechanisms acting alone or in combination could induce the myelosuppression associawas also negative (Figure 1 ). The patient recovered from ted with CMV. Furthermore, HHV-6 infection may also Acknowledgements contribute to post-BMT myelosuppression. All BMT patients with idiopathic bone marrow suppression had
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HHV-6 isolated from their bone marrow.
9 HHV-6-associated myelosuppression could also be explained by dysfunction of stromal cells and/or direct inhibition of hematopoietic progenitors.
10 In this case, severe thrombocytopenia References and neutropenia were observed before treatment with foscarnet and at a time when both CMV and HHV-6 were 1 Jabs DA. Controversies in the treatment of cytomegalovirus detectable in the peripheral blood. CMV retinitis was retinitis: foscarnet versus ganciclovir. Infec Agent Dis 1995; initially treated with a low dose of foscarnet (36 mg/kg/day) 4:132-142.
because of its side-effect of renal toxicity, but it could not 2 Ganly PS, Arthur C, Goldman JM, Schulenburg WE. Foscarhalt the progression of CMV retinitis. After treatment with net as treatment for cytomegalovirus retinitis following bone marrow transplantation. Postgrad Med J 1988; 64: 389-391. foscarnet (90 mg/kg/day) hematopoietic recovery occurred
